Chembio Receives $2.9M SBIR Grant to Develop Antibody-Based Tuberculosis Test

The test, which the company says showed sensitivity of 81 percent and specificity of 95 percent in pilot studies, uses a panel of polyepitope fusion proteins based on antigens involved in the antibody response to pulmonary tuberculosis.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.